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Background: We examined the association of tumor-derived hepatocyte growth factor (HGF) with the
clinicopathological features of gliomas and investigated the effect of HGF inhibition on the biological behavior of
tumor cells in vitro in order to determine whether HGF is a valuable prognostic predictor for glioma patients.
Methods: Seventy-six cases of glioma were collected. The tumor-derived HGF expression, cell proliferation index
(PI) and intratumoral microvessels were evaluated by immunohistochemistry. Correlation between immunostaining
and clinicopathological parameters, as well as the follow-up data of patients, was analyzed statistically. U87MG
glioma cells were transfected with short interference (si)-RNA for HGF, and the cell viability, migratory ability and
chemosensitivity to cisplatin were evaluated in vitro.
Results: Both high HGF expression in tumor cells (59.2%, 45/76) and high PI were significantly associated with
high-grade glioma and increased microvessels in tumors (P< 0.05). However, only histological grading (P= 0.004)
and high-expression of HGF (P= 0.008) emerged as independent prognostic factors for the overall survival of glioma
patients. The tumor-derived HGF mRNA and protein expressions were significantly decreased in vitro after
transfection of HGF siRNA. HGF siRNA inhibited the cell growth and reduced cell migratory ability. Moreover, HGF
siRNA transfection enhanced the chemosensitivity of U87MG glioma cells to cisplatin.
Conclusion: This study indicated that there was significant correlation among tumor cell-derived HGF, cell
proliferation and microvessel proliferation in gliomas. HGF might influence tumor progression by modulating the
cell growth, migration and chemoresistance to drugs. Increased expression of HGF may be a valuable predictor for
prognostic evaluation of glioma patients.
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Glioma is the most common type of primary brain tumor
with the worst prognosis in humans [1,2]. Increasing evi-
dence indicates that the rate of tumor cell proliferation, in-
vasion and induction of tumor angiogenesis might be
responsible for glioma progression. In contrast to other
solid tumors of the body, gliomas are characterized by an* Correspondence: lizhi@mail.sysu.edu.cn
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reproduction in any medium, provided the orinfiltration into surrounding brain parenchyma as individ-
ual cells along anatomic structures [3]. This might be the
reason why recurrence of gliomas frequently occurs within
a 2-cm margin of the primary mass after surgical resec-
tion. Recent studies have demonstrated that the biological
behavior of gliomas is associated with tumor cell migra-
tion ability, increased resistance to apoptosis, and
decreased sensitivity to chemotherapy or radiotherapy [4-
6]. However, the mechanisms involved in these processes
remain to be validated.
Hepatocyte growth factor (HGF) is a multifunctional
cytokine produced by both stromal and parenchymal cells. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Guo et al. World Journal of Surgical Oncology 2012, 10:128 Page 2 of 11
http://www.wjso.com/content/10/1/128that stimulates the motility and invasion of several cancer
cell types, and induces angiogenesis [7]. HGF plays an im-
portant role in tumor progression and is associated with
the prognosis of various human malignancies, including
carcinoma of the stomach, liver, lung and nasopharynx [8-
10]. In human gliomas, the expression of HGF and its re-
ceptor, c-Met, is associated with tumor grade [11]. Gene
transfer of HGF to glioma cells enhances their tumorigen-
icity, tumor growth and tumor-associated angiogenesis
[12]. Inhibition of HGF or c-Met expression leads to sup-
pression of in vivo tumor formation and growth [13]. A
recent study has also indicated that HGF levels in cerebro-
spinal fluid could be of prognostic value for predicting the
mortality and recurrence of glioblastoma [14]. At the cel-
lular level, the HGF and c-Met signaling pathway has been
demonstrated to influence tumor formation and malig-
nant progression by inducing cell cycle progression, tumor
cell migration, invasion and tumor angiogenesis in various
brain tumor cell lines, including those derived from gli-
oma, medulloblastoma and neuroblastoma [15-17]. More-
over, HGF can affect tumor malignancy by inhibiting basal
and radio-/chemotherapy-induced tumor cell death and
apoptosis. A few studies have shown that HGF protects
glioblastoma cells from DNA-damaging agents by activat-
ing PI3K/AKT anti-apoptotic pathways [13,18].
In the clinical setting, malignant gliomas are poorly
sensitive to anti-proliferative drugs, and less than 30% of
malignant gliomas respond to adjuvant chemotherapy.
Chemoresistance in gliomas is based on a complex net-
work of multiple pathophysiological mechanisms [19].
Although various molecular markers involved in chemo-
therapy resistance have been investigated, their direct
roles in the chemosensitivity and prognostic value of gli-
omas, except MGMT (O6-methylguanine DNA methyl-
transferase), remain controversial [20]. Recently, a study
has also exhibited that inhibition of c-Met enhanced the
chemosensitivity of glioma cell lines to cisplatin, but no
clear molecular mechanism involvement has emerged
[21]. The relationship, if any, between HGF and che-
moresistance in gliomas needs to be verified.
The aim of this study is to evaluate whether tumor-
derived HGF acts as a potent predictive factor for tumor
recurrence and prognosis for patients with gliomas, and
whether HGF indeed affects tumor progression by alter-




This study was carried out at the First Affiliated Hospital
of Sun Yat-sen University and the Guangdong General
Hospital (Guangzhou, China). Archival formalin-fixed,
paraffin-embedded specimens from 76 Chinese patients
who underwent surgery from 2001 to 2009 wererecruited. All patients had intracranial gliomas and no
history of other malignancies. Histological sections of
the primary resected surgical specimens were reviewed
by authoritative pathologists according to the criteria of
the WHO histological classification [22]. All experimen-
tal protocols were carried out with the approval of the
Committee on Use of Human & Animal Subjects in
Teaching and Research of Sun Yat-sen University
according to the Helsinki Declaration.
The patients were 52 males and 24 females with a me-
dian age of 47 years (range 8–76). Of these, 41 patients
had high-grade gliomas, WHO grade III− IV, including
23 glioblastoma multiformes, 15 anaplastic astrocytomas
and 3 anaplastic oligoastrocytomas. The other 35 had
low-grade gliomas, WHO grade I–II, including 21 fibril-
lary astrocytomas, 5 pilocytic astrocytomas, 5 oligo-
dendrogliomas, 3 ependymomas and 1 pleomorphic
xanthoastrocytoma. Since gliomas may present as ill-
defined lesions, various magnetic resonance imaging
(MRI) sequence combinations do not provide a unique
contour for tumor delineation. The extension of surgical
resection was conducted by preoperative imaging. For
presumed low-grade gliomas, manual segmentation was
performed with region of interest analysis to measure
tumor volumes (cm3) on the basis of FLAIR or T2 axial
slices. For high-grade gliomas, a similar segmentation
was made using the volume of contrast-enhancing tissue
seen on T1-weighted MRI. After surgery, patients were
followed up for a mean of 25.6 months (range, 3–
58 months). None of the patients had received chemo-
therapy or radiotherapy before surgery.
After surgery, patients with high-grade gliomas, includ-
ing glioblastoma multiforme and anaplastic astrocytoma,
underwent conventional external-beam radiotherapy with
a total dose of 60 Gy and continuous daily temozolomide
(75 mg per m2 of body-surface area per day, 7 days per
week from the first to the last day of radiotherapy), fol-
lowed by six cycles of adjuvant temozolomide (150–
200 mg per m2 for 5 days during each 28-day cycle). The
patients with astrocytoma (WHO grade II) were treated
with temozolomide 1 month after the initial surgery only.
The patients with oligodendrogliomas and oligoastrocyto-
mas underwent PCV chemotherapy [procarbazine, methyl-
1-(2-chloroethyl)-1-nitrosourea (CCNU), and vincristine]
every 6 weeks (42-day cycles) for two to five cycles [23-25].
Immunohistochemistry and scoring
The sections were subjected to immunostaining using a
ChemMate Envision/HRP Kit (DAKO, Denmark). Slides
were deparaffinized in xylene, rehydrated in decreasing
concentrations of ethanol and rinsed in phosphate-
buffered saline. After blocking with normal serum for
10 min, the slides were incubated with a 1:100 dilution
of rabbit polyclonal HGF antibody, a 1:500 dilution of
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of mouse monoclonal CD34 antibody (Santa Cruz Bio-
technology, Santa Cruz, CA, USA) for 60 min, respect-
ively. Slides were detected by ChemMate Envision/HRP
Kit for 30 min at room temperature, followed by devel-
oping with diaminobenzidine (DAB) for visualization.
Negative controls were provided by substituting non-
immune serum for the primary antibodies. The immu-
nostaining results were evaluated and scored semiquan-
titatively by two pathologists without knowledge of the
clinical data of patients. Evaluation of HGF expression
was calculated by a double scoring system (stain inten-
sity times stain area) as previously described [26]. Stain
intensity was scored as 0 for no staining, 1 for weak
staining, 2 for moderate staining and 3 for strong stain-
ing. The staining area was scored as 1 for less than 35%,
2 for 35–75% and 3 for >75% of tumor cells. High ex-
pression of HGF was defined when the immunostaining
score was ≥ 4, whereas low expression of proteins was
defined as a score <4. The proliferation index (PI) of gli-
omas was determined according to a previous descrip-
tion. Briefly, the percentage of ki-67-positive nuclei was
counted in ten high-power fields in the areas with the
highest density of labeled nuclei. The PI of each sample
was the mean of the independent percentage of ki-67-
positive signals by two observers. The high PI was
defined as a value greater than 5%, whereas low PI of
tumor was defined as a value ≤5% [22]. The counting of
microvessels in gliomas was evaluated by the previously
reported method [27]. In brief, intratumoral microvessel
density (IMD) was observed in areas of the most intense
neovascularization or hotspots in the tumor by light mi-
croscopy. After the area of the highest neovasculariza-
tion had been determined, single microvessels were
manually counted on a × 200 field. Any brown-stained
endothelial cell or cell cluster that was clearly separated
from the adjacent microvessels was considered as a sin-
gle, countable microvessel, and the IMD value of each
sample was the mean of the independent microvessels
counted by two observers.
Cell culture and reagents
In this study, the human U87MG cell line (HGF high-
expressed glioma cell line [28]) was used. U87MG cells
were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) with 10% heat-inactivated fetal calf serum
(FCS) and antibiotics (50 U/ml penicillin and 100 mg/ml
streptomycin, Gibco/Invitrogen) at 37°C in a humidified
incubator with 5% CO2.
Transfection of glioma cells with small interfering RNA
(siRNA) targeting HGF
Human HGF siRNA (siHGF) and nontargeting siRNA
control (siControl) were designed and synthesized by RiboBiotechnology Co. (Beijing, China). The sequence was
identified to be specific to the human HGF gene by using
the BLAST search of the NCBI database. siControl was
used for negative control purposes. siRNAs were reconsti-
tuted, and subsequent transfections were conducted in
six-well plates using TurboFect siRNA Transfection re-
agent (Fermentas, USA), according to the manufacturer’s
instructions. In brief, U87MG cells were seeded into six-
well plates with a density of 2 × 105 cells/well. Once the
cells reached 80% confluence, they were treated with ei-
ther siHGF or siControl (50 nM) complexed with Turbo-
Fect according to the manufacturer’s instructions. Ten
percent FCS was added 4 h after transfection, and fresh
DMEM with 10% FBS was added as needed after 24 h.
Cells were collected at 48 h after transfection to assess
HGF protein levels by Western blot and the other func-
tional assays listed in the following sections.
Polymerase chain reaction (PCR) for the detection of HGF
mRNA expression levels
U87MG cells were transfected for 48 h, and total RNA
was isolated from cells using Trizol reagent (Sigma-
Aldrich, USA) according to the manufacturer’s instruc-
tions. First-strand cDNA (20 ul) was synthesized from 2
ug total RNA using oligo (dT) primers. An aliquot (2 ul)
of cDNA was used as template for PCR amplification
with primers specific for HGF (sense primer: 5´CCA
CACGAACACAGCTATCGGGG -3’; antisense primer:
5´-TGGGAGCAGTAGCCAACTCGGA-3´, Invitrogen,
USA). PCR was performed in an automatic thermal
cycler (Perkin-Elmer-Cetus, Norwalk, CT). Samples were
amplified through 35 consecutive cycles with annealing
temperature of 57°C. A 10-ul volume of each PCR prod-
uct was analyzed by electrophoresis on 1.5% agarose gel
containing 0.5 ug/ml ethidium bromide, and the bands
were visualized under ultraviolet light.
Western blotting assay
Transfected U87MG cells were lysed as described previ-
ously [29]. Equal protein samples were subjected to 12%
SDS-PAGE electrophoresis, followed by the transfer to a
polyvinylidene fluoride (PVDF) membrane, blocking in
5% fat-free milk and incubation with HGF (at 1:500 dilu-
tion) or GADPH antibody (Abcam, USA) at 4°C over-
night. Detection was performed using horseradish
peroxidase-conjugated secondary antibody and enhanced
chemiluminescence reagents from Amersham (Amer-
sham Life Sciences, UK). The relative optical density
(ROD, ratio to GADPH) of each blot band was quanti-
fied by NIH Image software (Image J 1.36b).
Immunofluorescence staining
Transfected U87MG cells were plated on coverslips,
fixed with 4% paraformaldehyde/phosphate-buffered
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Triton X-100 in PBS for 2 min, and then incubated in
PBS containing 5% skim milk for 1 h at room
temperature. Cells were incubated with anti-HGF anti-
body (1:100, Abcam, USA) for 1 h at room temperature,
followed by incubation with goat anti-rabbit IgG/Cy3
(1:500, Invitrogen, USA) for 1 h and nuclear counter-
staining with DAPI.MTT assay
The effect of siHGF on the viability of U87MG glioma
cells was measured by 3-[4, 5-dimethylthiazol-2-thiazo-
lyl]-2, 5-diphenyltetrazolium bromide (MTT) assay as
described previously [30]. Briefly, U87MG cells were
seeded at 1 × 105 cells/well into 96-well plates in quintu-
plicate, and transfected with siHGF or siControl for 24,
48 and 72 h, respectively. Four hours before the desired
time points, 20 ul of 5 mg/ml MTT was added into each
sample. The plates were then incubated at 37°C in a 5%
CO2/95% air atmosphere for 4 h. Thereafter, the
medium was discarded, and 150 ul of DMSO was added
into each well. The absorbance was determined at
490 nm by an enzyme-linked immunosorbent assay
reader. Results represented the OD ratio between theFigure 1 Immunohistochemical staining of glioma tissues. a Strong an
positive staining of HGF was shown focally and weakly in low-grade gliom
gliomas. Most high-grade gliomas had a high proliferation index (PI). d Intr
endothelial cells for anti-CD34. Any brown-staining endothelial cell or cell c
considered as a single, countable microvessel. (a-c immunohistochemical s
staining× 200).siRNA-treated and untreated cells at the same indicated
time points.In vitro wound healing assay
Migratory ability of U87MG cell was measured using the
in vitro wound healing assay. Cells were seeded in six-
well plates and transfected with siHGF or siControl for
48 h. Transfected cells were grown to 100% confluence.
Wounds were created by scraping monolayer cells with
a sterile pipette tip. At 0, 12, 24 and 48 h after the cre-
ation of wounds, wound distances were measured at
each time point and expressed as the average percent of
wound closure by comparing the zero time.Cisplatin cytotoxicity assay
For the acute cytotoxicity assay, U87MG cells were
seeded at 1 × 104 cells per well in 96-well plates, and
were transfected by siHGF or siControl for 48 h, and
subsequently exposed to cisplatin at final concentrations
of 0.5, 1.0, 2.0, 4.0 or 8.0 ug/ml for 24 h in triplicate
wells. Cell survival was determined using a previously
described colorimetric MTT assay. Then 20 ul of 5 mg/
ml MTT was added to each well, and the plates were
incubated for 4 h at 37°C. The absorption was read atd diffuse expression of HGF was found in high-grade glioma; b
as. c The extent of Ki-67-positive signal represented the proliferation of
atumoral microvessels of gliomas were highlighted by staining
luster that was clearly separated from the adjacent microvessels was
taining with original magnification, ×400; d immunohistochemical
Table 1 Correlation among HGF expression, cell
proliferation, IMD value and clinicopathological
parameters of patients with gliomas










High grade (n=41) 10 31 3 38 24.78 ± 10.30
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cell viability was calculated by the ratio of absorbance
units of transfected cell samples to the mean absorbance
units of the control cell samples. All the experiments
were repeated at least three times. The IC50 value is
defined as concentration of cisplatin that is required for
a 50% reduction in absorbance calculated from the
growth curves.Low grade (n= 35) 21 14 30 52 19.57 ± 8.62
P=0.001 P= 0.001 P= 0.021
Tumor recurrence
No (n= 57) 27 30 26 31 21.70 ± 9.83
Yes (n= 19) 4 15 76 12 24.42 ± 9.89




24 7 18.24 ± 6.41
High expression
(n= 45)
9 36 25.23 ± 10.82
P= 0.001 P= 0.001
Cell proliferationStatistical analysis
All statistical analysis was carried out by SPSS 13.0 soft-
ware for Windows. The chi-square test was used to as-
sess HGF expression and PI with clinicopathological
characteristics. Vascular density and data derived from
experiments in vitro were given as the mean ± SD as
indicated. Data were analyzed by one-way ANOVA with
Dunnett’s post hoc test and Tukey’s post hoc test for
multigroup comparisons. The survival curve of patients
was determined by the Kaplan-Meier method and Cox
regression, and statistical evaluation was performed
using the log rank test. A value of P< 0.05 was consid-
ered statistically significant.Low PI (n= 33) 24 9 19.31 ± 8.32
High PI (n= 43) 7 36 24.73 ± 10.37
P=0.001 P= 0.016
aChi-square test.
bIndependent sample T test.Results and discussion
Correlation among HGF expression, cell proliferation and
microvessel counts in gliomas
Positive cytoplasmic HGF staining was observed in
tumor cells of gliomas in various degrees (Figures 1a, b).
High HGF expression in tumor cells was observed in
59.2% (45/76) of glioma tissues. High HGF expression
was significantly associated with higher histological
grading (WHO grades III and IV) and tumor recurrence
(P= 0.001). Nuclear-positive signals with intense dark
brown staining for proliferative tumor cells were
observed in gliomas labeled by ki-67 antibody
(Figure 1c). The mean proliferation index (PI) values
were significantly higher in cases with high HGF expres-
sion than those in cases with low expression of HGF
(P= 0.001). Higher PI values were more easily observed
in the cases with higher histological grading (P= 0.001).
However, the PI value showed no correlation with other
clinicopathological parameters, including tumor recur-
rence and microvessel counts in tumors. Microvessels in
gliomas, specifically stained by anti-CD34 immunostain-
ing, were observed in all specimens and scored as intra-
tumoral microvessel density (IMD) (Figure 1d). The
mean IMD value was 22.4/HPF, but with great individual
variation (range 10–50). The IMD was significantly
higher in tumors with high expression of HGF or with
high-grade gliomas. However, there was no significant
correlation found between the IMD value and tumor re-
currence (Table 1).Association of HGF expression with survival of patients
with gliomas
The 76 patients were followed up from 3 to 58 months
with a mean period of 25.6 months, and 46 (60.5%) died
of their tumor during this period. In univariate analysis,
high-grade tumor, high-expression of HGF and higher PI
were significantly associated with a short survival time of
patients with gliomas. There was no significant difference
in survival time between the patients with or without
tumor recurrence (Figure 2, Table 2). However, in multi-
variate analysis, only histological grade and high expres-
sion of HGF in gliomas were independently associated
with survival. Other clinical parameters, such as age, gen-
der, microvessels, cell proliferation and tumor recurrence,
showed no association with patient survival (Table 3).Effect of HGF siRNA on HGF expression in glioma cells
in vitro
U87MG glioma cells were transfected with siHGF and
siControl for a period of 48 h. The transfected cells were
highlighted by red dot-like fluorescence under the fluor-
escence microscopy. The ratio of transfection in U87MG
glioma cell was 50%. We investigated the status of HGF
in glioma cells by immunofluorescence staining, West-
ern blotting and RT-PCR assay. By immunofluorescence
Figure 2 Kaplan-Meier survival analysis in 76 patients with gliomas. a Kaplan-Meier curve showing the patients with high-grade tumor have
a lower survival rate than those with low-grade tumor. b Patients with a tumor with high HGF expression had a lower survival rates than those
with low HGF expression tumors. c A significant difference in survival rates was found between patients with a high proliferation index and low
index in their tumor. d There was no significant difference in survival rates between the patients with or without tumor recurrence.
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was significantly decreased in U87MG cells with siHGF
treatment compared to those with siControl transfection
and untreated cells (Figure 3a and b). By RT-PCR assay,
we found the HGF mRNA level was also dramatically
decreased in the cell after 48 h of siHGF transfection
(Figure 3c).
Effect of HGF siRNA on growth inhibition and migratory
ability of glioma cells in vitro
The effect of HGF siHGF on cell viability was evaluated
by MTT assay. As shown in Figure 4a, siHGF transfec-
tion resulted in inhibition of glioma cell viability. The in-
hibitory effect of siHGF on glioma cell growth was
strongest after 48 h of transfection. There was a signifi-
cant difference in cell growth inhibition between the
HGF siRNA-transfected cells and the control cells (P
<0.05). Wound healing assay showed that the migration
in HGF siRNA-transfected cells was markedly decreased
compared with those in control siRNA-transfected and
untreated cells (Figure 4b).siHGF-induced chemosensitivity enhancement to cisplatin
in glioma cells in vitro
We used a cytotoxicity MTT assay to further investigate
the effect of HGF siRNA on the chemosensitivity to cis-
platin in glioma cells. Exposure of HGF siRNA-
transfected U87MG cells to different concentrations of
cisplatin induced significant proliferative inhibition.
When the concentration of cisplatin was 8 ug/ml; the
viability of HGF siRNA-transfected U87MG cells showed
no significant difference compared with those of the
siControl-transfected and untreated cells (Figure 5).
Meanwhile, the IC50 concentration of cisplatin for
U87MG cells decreased significantly from 7.06 ug/ml in
control cells and 2.01 ug/ml in siHGF-transfected cells,
respectively, which indicated that siHGF might be one of
the factors that enhanced the chemosensitivity of glioma
cells to cisplatin.
As a multifunctional cytokine, HGF and its receptor
tyrosine kinase, c-Met, have emerged as key determinants
of tumor development and progression, including brain
tumors [31]. The extent of HGF expression as a








<47 (n= 37) 33.98 ± 3.67 26-41 0.324
≥47 (n= 39) 26.63 ± 3.16 20-32
Gender
Male (n= 52) 31.46 ± 3.09 25-37 0.985




13.61 ± 1.47 10-16 0.001
Low grade (WHO
I-II) (n= 35)
52.45 ± 2.31 47-56
Tumor recurrence
No (n= 57) 30.49 ± 3.01 24-36 0.672
Yes (n= 19) 30.42 ± 4.13 22-38
HGF expression
High expression (n= 45) 21.46 ± 2.93 15-27 0.001
Low expression (n =31) 43.67 ± 3.04 37-49
Cell proliferation
High PI (n= 43) 14.41 ± 1.60 11-17 0.001
Low PI (n= 33) 53.44 ± 2.13 49-57
Intratumoral microvessel
density
≥ Mean IMD value (n=27) 24.46 ± 4.05 16-32 0.079
< Mean IMD value (n=49) 34.55 ± 3.13 28-40
*Log rank test.
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cellular carcinoma, gastric cancer and breast cancer
[9,32,33]. In gliomas, HGF-associated tumor growth and
angiogenesis have been demonstrated. The HGF expres-
sion level could be of prognostic value for predicting the
mortality and recurrence of tumors. This study showedTable 3 Cox regression model for multivariate analyses of
prognostic factor in gliomas
Variable Hazard ratio 95% confidence
interval
P value
Age (<47 vs. ≥ 47) 0.924 0.446-1.914 0.833
Gender (male vs. female) 1.144 0.534-2.452 0.728
Histological grade
(WHO I-II vs. WHO III-IV)
7.282 1.849-28.671 0.004
Tumor recurrence (no vs. yes) 0.615 0.269-1.403 0.248
Cell proliferation
(low PI vs. high PI)
3.898 0.848-17.913 0.080
Angiogenesis (IMD value) 0.992 0.961-1.025 0.666
HGF expression (low vs. high) 3.327 1.357-8.152 0.008that high levels of HGF expression were found in glioma
specimens with higher histological grade and tumor recur-
rence, and these were closely associated with shorter pa-
tient survival in both univariate and multivariate analysis.
These results corroborate previous findings that suggest
HGF as a valuable prognostic factor in patients with
gliomas.
Previous studies have indicated that HGF-induced cell
proliferation and anti-apoptosis are involved in the pro-
gression of tumors [28,31]. Moreover, accumulated evi-
dence revealed that HGF might be identified as the most
potent stimulator of glioma cell migration when com-
pared with numerous other growth factors previously
associated with glioma motility [34]. In this study, we
found that the reduction of tumor-derived HGF expres-
sion resulted in inhibition of cell proliferation and
impaired the ability of cell migration in vitro. We postu-
lated that tumor cell-derived HGF was likely to influence
the prognosis of glioma patients by way of an autocrine
regulatory loop [17,35]. In the clinical setting, measure-
ment of the HGF level in tumor cells might be used as a
predictive element directly associated with the degree of
malignancy and the hazard rating of recurrence of gli-
omas. In addition, there is some debate over aggressive
therapy for low-grade gliomas because neither histo-
pathological nor clinical data are currently taken as reli-
able recurrence predictors for low-grade gliomas,
especially for grade I tumors. However, in this study, we
found that all pilocytic astrocytomas (WHO grade I)
with higher HGF expression recurred during the follow-
up period despite the low level of proliferative activity
(data not shown). Although the number of grade I gli-
omas examined in this study was not sufficient to allow
us to draw a definite conclusion, these findings indicated
that high expression of HGF could be used as a pre-
dictor for the recurrence of gliomas and could help de-
termine whether aggressive therapy is necessary,
particularly for those gliomas with lower WHO grades.
Analysis of a wide range of gliomas showed a gross cor-
relation of cell proliferation with histological grade of
tumor. The proliferation index, as determined by the anti-
body Ki-67/MIB-1, however, showed great regional vari-
ation within a tumor, and might overlap with values for
low- and high-grade gliomas. Despite the higher prolifera-
tion indices observed in high-grade gliomas, an association
between proliferation index and clinical outcome has not
been demonstrated [36]. HGF-induced in vitro prolifera-
tion and anchorage-independent growth have been
demonstrated in various brain tumor cell lines [15-17] in
which HGF plays a mitogenic role in tumor cells at least
partly by mediating the G1/S cell cycle transition. In this
study, we found tumor-derived HGF was closely associated
with cell proliferation in both in vivo and in vitro investi-
gations. However, multivariate analysis for overall survival
Figure 3 HGF siRNA inhibited tumor cell-derived HGF expression. a Immunofluorescence assay showed that tumor cell-derived HGF protein
expression was significantly decreased in U87MG glioma cells with HGF siRNA transfection (bottom) when compared with control siRNA
transfected cells (middle) and mock (top) (immunofluorescence staining with original magnification, ×400). Western blot assay (b) and RT-PCR (c)
exhibited that HGF protein and mRNA expression levels were decreased in the cells with HGF siRNA transfection.
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not an independent predictive factor for the prognosis of
gliomas, although high PI was significantly correlated with
a high histological grade and a decreased survival rate in
patients. In contrast to our results, however, several studies
have shown that the cell proliferation potential was inde-
pendently correlated with outcome in intracranial gliomas
[37,38]. Further investigations with larger case numbers
and unabridged follow-up data should be carried out to
clarify whether the detection methods and sample size are
responsible for these discrepancies.
Massive formation of blood vessels is associated with a
high histological grade, which is unfavorable for the out-
come of gliomas. Significant evidence exists showing
that HGF promotes the angiogenesis of brain tumors.
HGF could be detected in the tumor blood vessels and
induce tumor endothelial cell proliferation andmigration by paracrine and autocrine mechanisms [39].
In addition to its direct angiogenic activities, HGF could
enhance the induction of angiogenic factor in gliomas,
including VEGF, bFGF and IL-8. In the present study,
we found that microvascular proliferation in gliomas
was significantly correlated with high expression of
tumor-derived HGF, as well as higher histological grade.
However, multivariate analysis for overall survival in
patients indicated that angiogenesis in tumors was not
an independent predictive factor for the prognosis of gli-
omas. Although the expression of HGF in tumor endo-
thelial cells and the expression of angiogenic factors
were not analyzed in this study, it is reasonable to be-
lieve that tumor-derived HGF can stimulate tumor neo-
vascularization at least partly by mediating the secretion
of relevant angiogenic factors via a paracrine
mechanism.
Figure 4 The effect of HGF inhibition on cell growth and migratory abilities of glioma cells. a MTT assays were performed in the U87MG
glioma cell line. Cells were cultured in a 96-well plate and transfected with HGF siRNA or control siRNA for 24, 48 and 72 h points with an
average of five independent experiments in each group (*P <0.05 versus control cells; one-way ANOVA). b Optical microscopic images of in vitro
wound healing at 0, 12, 24 and 48 h after the creation of wounds. HGF siRNA-transfected cells displayed significantly slower wound closure at all
time points compared with control siRNA-transfected cells.
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http://www.wjso.com/content/10/1/128Gliomas are frequently resistant to therapy even after
aggressive surgical resection, external beam radiation
therapy and the maximum tolerated chemotherapy dose
with agents such as temozolomide or nitrosourea.Enhancement of chemosensitivity is one of the major
strategies to overcome the multidrug resistance and un-
desirable side effects of chemotherapy. The mechanism
of chemoresistance in tumor therapy is very complicated
Figure 5 HGF siRNA-induced enhancement of chemosensitivity
to cisplatin. Sensitivity curve of the U87MG cell line toward
cisplatin via MTT assay. Growth inhibition of HGF siRNA-
transfected cells was observed after exposure to different
concentrations of cisplatin for 24 h (*P< 0.05 versus control cells,
one-way ANOVA).
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http://www.wjso.com/content/10/1/128and remains poorly understood. Several studies have
demonstrated that inhibition of PI3K/AKT signaling and
p44/42 MAPK activation is an efficient way to attenuate
the resistance of chemotherapy [40,41]. It has been
revealed that HGF-activated c-Met expression can pro-
tect glioblastoma cells and tumor xenografts from DNA-
damaging agents just by activating the PI3K/AKT path-
way [18]. In the present study, we found that inhibition
of tumor-derived HGF by siRNA could dramatically en-
hance the sensitivity of tumor cells to cisplatin in vitro.
This indicated that inhibited expression of HGF or inter-
fering c-Met activation in gliomas appears to be a prom-
ising strategy for developing a therapeutic approach to
treat this malignant tumor. Cisplatin alone or in com-
bination with other chemotherapy agents has been used
to treat low-grade gliomas or recurrent glioblastoma
[42,43], because local chemotherapy of glioblastoma with
cisplatin followed by irradiation proved to be well toler-
ated and effective [44]. However, cisplatin is not a first-
line drug for glioma chemotherapy because of its limited
ability to reach an effective concentration at the tumor
site. Therefore, an HGF inhibitor combined with cis-
platin might be a potential application to enhance the
chemosensitivity of gliomas with higher levels of HGF.Conclusion
Although the precise factors responsible for a poor prog-
nosis in gliomas have not been identified, this study indi-
cates high expression of HGF in tumor cells may play a
critical role in tumor progression and is a valuable pre-
dictor for prognosis evaluation in glioma patients. To
the best of our knowledge, the present data provide a
correlation between the HGF status in tumor cells andchemosensitivity to cisplatin in vitro for the first time.
This might provide a new promising strategy for a thera-
peutic approach for patients with gliomas.
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